Committee Chairman Sen. Chuck Grassley, R-Iowa, and Sen. Ron Wyden, D-Ore., sent letters to the three leading manufacturers of insulin — Eli Lilly, Novo Nordisk and Sanofi — seeking answers to why the 100-year-old lifesaving drug is increasing in price.
In the letter, the senators pointed to sharp insulin price increases at all three companies. In one instance, the letter asks why Eli Lilly’s Humalog rose 585 percent between 2001 and 2015.
Senators are asking the companies to discuss their pricing strategies, their research and development costs and revenue from insulin sales.
“We are concerned that the substantial increases in the price of insulin over the past several years will continue their upward drive and pose increasingly severe hardships, not only on patients that require access to the drug in order to stay alive, but also on the taxpayer,” the senators wrote, according to Reuters.
More articles on pharmacy:
5 recent pharma bankruptcies
Top 10 fatal or harmful prescribing errors
Civica Rx will start as middleman for drugmakers, hospitals, Bloomberg says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.